Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma
Authors:
Open Access
- 1 January 2022
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 13 (3) , 951-964
Abstract
Resistance to sorafenib has been documented in hepatocellular carcinoma (HCC) patients. We investigated: (i) the correlation between adenosine triphosphate citrate lyase (ACLY) expression and sorafenib resistance in HCC; and (ii) if targeted inhibition could reverse sorafenib resistance. Samples of HCC tissue were obtained from patients and ACLY expression was measured. PET/CT was employed to measure maximum standard unit value (SUVmax) in HCC patients before and after sorafenib treatment. Using HepG2 cells, we created a sorafenib-resistant cell line. Glucose metabolism and lipid synthesis in HCC cells were tested using 14C-glucose. Disulfide-crosslinked polyethylenimine (SS-PEI)-mediated plasmid transfection was carried out, followed by creation of an HCC model in mice. SUVmax of HCC lesions was closely related to ACLY expression. Patients with high ACLY expression were not sensitive to sorafenib therapy. Lipid metabolism was more active in sorafenib-resistant HCC cells. ACLY expression was higher in sorafenib-resistant cells and HCC-cell sensitivity to sorafenib increased after ACLY-knockout. The latter reversed sorafenib resistance in HCC cells more significantly under hypoxic conditions. SS-PEI/proline-modified short hairpin-(psh)RNA-ACLY plus sorafenib inhibited the growth of drug-resistant cells significantly. These data suggest that ACLY downregulation can reverse sorafenib resistance, and that SS-PEI can be used to mediate shRNA-ACLY transfection in HCC treatment.Keywords
This publication has 27 references indexed in Scilit:
- Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registryThe American Journal of Surgery, 2017
- Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast CancerClinical Cancer Research, 2016
- Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progressionCellular and Molecular Life Sciences, 2015
- HIF‐1 at the crossroads of hypoxia, inflammation, and cancerInternational Journal of Cancer, 2015
- ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and TreatmentCurrent Drug Targets, 2015
- Dual-degradable disulfide-containing PEI–Pluronic/DNA polyplexes: transfection efficiency and balancing protection and DNA releaseInternational Journal of Nanomedicine, 2013
- Cellular Fatty Acid Metabolism and CancerCell Metabolism, 2013
- Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivoJournal of Controlled Release, 2012
- A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproductionMolecular Cancer Therapeutics, 2008
- Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetateNuclear Medicine and Biology, 2004